v3.19.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2018
Dec. 31, 2017
Current Assets    
Cash and cash equivalents $ 22,154,251 $ 9,763,067
Short-term investments 5,570,027
Accounts receivable 28,538 14,833
Prepaid expenses and other current assets 961,317 1,967,257
Total Current Assets 28,714,133 11,745,157
Property and Equipment, net 643,146 286,891
Other Assets    
Restricted cash 2,292
In-process R&D 5,866,000 5,866,000
Goodwill 2,189,338 2,189,338
Deposits 351,220 69,798
Deferred financing costs 30,000
Total Other Assets 8,406,558 8,157,428
Total Assets 37,763,837 20,189,476
Current Liabilities    
Accounts payable 974,619 1,033,680
Deferred revenue, current portion 1,032,539 7,026,388
Contingent consideration, current portion 1,187,000
Accrued expenses and other liabilities 1,678,051 2,276,431
Total Current Liabilities 4,872,209 10,336,499
Long Term Liabilities    
Other long-term liabilities 213,724 160,559
Deferred tax liability 316,733 1,302,220
Deferred revenue, net of current portion 200,000
Contingent consideration, net of current portion 1,918,225 2,609,289
Total Liabilities 7,520,891 14,408,567
Commitments and Contingencies
Stockholders' Equity    
Common stock, $.0002 par value; 100,000,000 shares authorized, 32,492,144 and 4,200,310 issued and outstanding at December 31, 2018 and 2017, respectively 6,499 840
Additional paid-in capital 114,883,135 76,382,262
Accumulated deficit (84,580,180) (68,846,326)
Accumulated other comprehensive loss (19,904) (166,025)
Total Stockholders' Equity - Heat Biologics, Inc 30,289,550 7,370,751
Non-Controlling Interest (46,604) (1,589,842)
Total Stockholders' Equity 30,242,946 5,780,909
Total Liabilities and Stockholders' Equity $ 37,763,837 $ 20,189,476

Source